期刊文献+

分化型甲状腺癌67例临床分析 被引量:3

Clinical analysis of 67 cases with differentiated thyroid carcinoma
原文传递
导出
摘要 目的探讨分化型甲状腺癌的诊治方法选择。方法回顾性分析我院治疗的67例分化型甲状腺癌临床资料。结果失访12例,复发9例,死亡2例,5年生存率94%,10年生存率89%。结论对分化型甲状腺癌,主张行患侧腺叶加峡部切除及对侧腺叶次全切除。对颈淋巴结阳性,同时行患侧功能性颈淋巴结清扫术;术后行131I治疗者,复发和死亡率明显低于仅行甲状腺激素替代治疗或未行任何治疗者。 Objective To explore the differentiated thyroid cancer diagnosis and treatment options. Methods Clinical data of 67 patients with differentiated thyroid carcinoma from 1996 to 2008 were reviewed ret- rospectively. Results 12 cases lost follow-up, 9 cases recurred, 2 cases died, the 5-year and 10-year survival rate were 94% and 89%. Conclusions Excision of the tumor located lobe, isthmus and subtotal lobectomy for the contralateral lobe is appropriate for differentiated thyroid carcinoma. Tumor ipsilateral side functional cervical dissection is appropriate for patients with cervical lymph node metastasis. 131I treatment can significantly lower the recurrence and mortality compare to those patients only treated with thyroid hormones replacement or without any treatment after poeration.
出处 《中华内分泌外科杂志》 CAS 2010年第2期95-97,共3页 Chinese Journal of Endocrine Surgery
关键词 分化型甲状腺癌 外科手术 Differentiated thyroid carcinoma(DTC) Surgery
  • 相关文献

参考文献13

二级参考文献59

共引文献169

同被引文献21

  • 1Mitchell I,Livingston EH,Chang AY,et al.Trends in thyroid cancer demographics and surgical therapy in the United States[J].Surgery,2007,142(6):823-828.
  • 2Bilimoria KY,Bentrem DJ,Ko CY,et al.Extent of surgery affects survival for papillary thyroid cancer[J].Ann Surg,2007,246(3):375-381.
  • 3Machens A,Holzhausen HJ,Dralle H.The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma[J].Cancer,2005,103(11):2269-2273.
  • 4I.eeman - Neill R J, Brenner AV, Little MP, et al. RET/PTC and PAX8/PPAR γ chromosomal rearrangements in post - Chernobyl thyroid cancer and their association with iodine - 131 radiation dose and other characteristics [ J]. Cancer, 2013, 119 (10) : 1792 - 1799.
  • 5Molinaro E, Giani C, Agate L, et al. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low- activity 131I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10 - year follow-up [J]. J Clin Endocrinol Metab, 2013, 98 (7) : 2693 - 270O.
  • 6Remy H, Coulot J, Borget I, et al. Thyroid cancer patients treated with 131I: radiation dose to relatives after discharge from the hospital [J]. Thyroid, 2012, 22 (1): 59-63.
  • 7Mallick U, Harmer C, Yap B, et al. Ablation with low - dose radioiodine and thyrotmpin alfa in thyroid cancer [ J ]. N Engl J Med, 2012, 366 (18): 1674-1685.
  • 8Hewamanna R, Loganathan N, Perera DKA. Releasing thyroid cancer patients from the hospital based on dose rate measurement after 131I activity administration [ J ]. Journal of the National Science Foundation of Sri Lanka, 2014, 42 (2) : 137 - 141.
  • 9Quach A, Ji L, Mishra V, et al. Thyroid and hepatic function after high - dose ^131I - metaiodobenzylguanldine (^131I - MIBG) therapy for neuroblastoma [J]. Pediatr Blood Cancer, 2011, 56 (2): 191 - 201.
  • 10Jentzen W, Hobbs RF, Stahl A, et al. Pre - therapeutic ( 124 ) I PET (/CT) dosimetry confirms low average absorbed doses per administered (131) I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer [ J ]. Eur J Nucl Med Mol Imaging, 2010, 37 (5): 884-895.

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部